
| Tocilizumab mas glucocorticoides para tratar pacientes graves y en situacion critica infectados por COVID-19 Experiencia de un centro #MMPMID32718713Jimenez-Britez G; Ruiz P; Soler XMed Clin (Barc) 2020[Nov]; 155 (9): 410-411 PMID32718713show ga
?|*Betacoronavirus[MESH]|Aged[MESH]|Antibodies, Monoclonal, Humanized/*therapeutic use[MESH]|Bacterial Infections/epidemiology[MESH]|COVID-19[MESH]|COVID-19 Drug Treatment[MESH]|Combined Modality Therapy[MESH]|Comorbidity[MESH]|Coronavirus Infections/complications/*drug therapy/epidemiology/therapy[MESH]|Critical Illness/*therapy[MESH]|Cytokine Release Syndrome/*drug therapy/etiology[MESH]|Diabetes Mellitus/epidemiology[MESH]|Female[MESH]|Humans[MESH]|Hypertension/epidemiology[MESH]|Length of Stay/statistics & numerical data[MESH]|Male[MESH]|Methylprednisolone/*therapeutic use[MESH]|Middle Aged[MESH]|Oxygen Inhalation Therapy[MESH]|Pandemics[MESH]|Pneumonia, Viral/complications/*drug therapy/epidemiology/therapy[MESH]|Respiration, Artificial[MESH]|SARS-CoV-2[MESH]|Superinfection/epidemiology[MESH]
  
DeepDyve Pubget Overpricing | 
|